ClinicalTrials.gg
RecruitingNCT04510129Updated Mar 12, 2025

A Multicenter Cancer Biospecimen Collection Study

An observational study in Cancer of Head and Neck, Lung Cancer, Nonsmall Cell and Small-cell Lung Cancer, sponsored by Cofactor Genomics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Primary conditionEsophageal Squamous Cell CarcinomaRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal Squamous Cell Carcinoma
Why
  1. The study's listed conditions name Esophageal Squamous Cell Carcinoma, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cofactor Genomics, Inc. · Observational

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,650
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 42 open to participants now, 50 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.

Started
2020
with 9 others
Observational
6 of 138
5 open now
Primary completion
2027-02
later than 9 of 49 live
Registered
85th of 138
by date

Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is one of 10 that started in 2020, is one of 6 observational ones, reaches primary completion later than 9 of the 49 other live ones, and was the 85th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

42 of the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Read the detailed description

This study will establish a prospective cohort of pre-treatment tumor specimens with correlated de-identified clinical and demographic data and tissue histology from cancer patients who are undergoing treatment with PD-1/PD-L1 inhibitors. Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.

The study will not require a study-specific tumor biopsy; any biopsies taken prior to treatment as part of standard of care are eligible for this study. Biopsies must not have been taken after immunotherapy treatment began.

Participants will be asked to provide their consent for the potential use of their biospecimens in subsequent studies for the development and validation of a diagnostic test.

03

Conditions studied

  • Cancer of Head and Neck
  • Lung Cancer, Nonsmall Cell
  • Small-cell Lung Cancer
  • Urothelial Carcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Cervical Cancer
  • Esophageal Squamous Cell Carcinoma
  • Triple Negative Breast Cancer
  • Hepatocellular Carcinoma
  • Renal Cell Carcinoma
  • Colorectal Cancer
04

In context

Esophageal Squamous Cell Carcinoma Reclassified

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 1,650 is above the median of 225 across 88 observational studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

Cofactor Genomics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Esophageal Squamous Cell Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who have undergone pre-anti-PD-1/PD-L1-treatment tumor biopsy or who are scheduled for tumor biopsy prior to anti-PD-1/PD-L1 treatment will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must have a disease of interest. Specifically, subject must have one of:

    1. head and neck squamous cell carcinoma (HNSCC)
    2. non-small-cell lung cancer (NSCLC)
    3. small cell lung cancer (SCLC)
    4. urothelial carcinoma (UCC)
    5. gastric or gastroesophageal junction adenocarcinoma
    6. cervical cancer
    7. esophageal squamous cell carcinoma (ESCC)
    8. triple-negative breast cancer (TNBC)
    9. hepatocellular carcinoma (HCC)
    10. renal cell carcinoma (RCC)
    11. colorectal cancer (CRC)
  2. Subject must have received, or be scheduled to receive, at least one dose of /PD-L1 immunotherapy for treatment of their cancer.
  3. Subject must have had, or will have, a tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  5. Willing to provide electronic per IRB-approved protocol.
  6. Able to speak, read, and comprehend English fluently.
  7. Subject is 18 years of age or older.
  8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to provide .
  2. Subject who does/did not have one of the cancers listed above (other histologies).
  3. Subject has already participated in this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,650 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • head and neck squamous cell carcinoma (HNSCC)

    Diagnostic Test: OncoPrism™ assay

  • non-small-cell lung cancer (NSCLC)

    Diagnostic Test: OncoPrism™ assay

  • small cell lung cancer (SCLC)

    Diagnostic Test: OncoPrism™ assay

  • urothelial carcinoma (UCC)

    Diagnostic Test: OncoPrism™ assay

  • gastric or gastroesophageal junction adenocarcinoma

    Diagnostic Test: OncoPrism™ assay

  • cervical cancer

    Diagnostic Test: OncoPrism™ assay

  • esophageal squamous cell carcinoma (ESCC)

    Diagnostic Test: OncoPrism™ assay

  • triple-negative breast cancer (TNBC)

    Diagnostic Test: OncoPrism™ assay

  • hepatocellular carcinoma (HCC)

    Diagnostic Test: OncoPrism™ assay

  • renal cell carcinoma (RCC)

    Diagnostic Test: OncoPrism™ assay

  • colorectal cancer (CRC)

    Diagnostic Test: OncoPrism™ assay

Interventions

  • Diagnostic testOncoPrism™ assay

    OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.

07

What researchers measure

Primary outcomes

  1. PD-L1/PD-1 inhibitor response

    No response to treatment with PD-L1/PD-1 inhibitor and response to treatment with PD-L1/PD-1 inhibitor.

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
  • Curebase
    San Francisco, California 94131, United States
    Recruiting
09

References and documents

Related links

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Feb 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 12, 2020
StartActual
Feb 5, 2020
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04510129
Lead sponsor
Cofactor Genomics, Inc.
Collaborators
Curebase Inc.
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Feb 5, 2020
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 12, 2025

Study contacts

Clinical Trial Coordinator
Contact
clinicaltrials@cofactorgenomics.com
(888) 602-0448
Jarret Glasscock
study director · Cofactor Genomics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion